1,914.5
+4.16%
Close of 9 Nov 2026, in JPY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Sumitomo Pharma Co
Its shares trade on Tokyo Stock Exchange under the ticker 4506.T. It has been listed since 16 May 1949. In the fiscal year to 31 March 2026, it reported revenue of ¥453.29bn and net income of ¥106.86bn. At that date it held total assets of ¥804.57bn and shareholders' equity of ¥292.47bn.
Sumitomo Dainippon Pharma Co., Ltd. engages in manufacture, sale, import, and export of pharmaceutical products. The company is headquartered in Osaka, Osaka-Fu. The firm operates in four segments. The Japan segment manufactures and sells medical drugs. The North America segment manufactures, develops, purchases and sells ethical drugs. The China segment manufactures and sells ethical drugs through its consolidated subsidiary. The Other Overseas division is involved in the development of its products in Europe. The firm is also engaged in the manufacture, purchase, sale and supply of food materials and additives, chemical products, veterinary drugs, diagnostic products and inspection services of clinical pathology for animal, the manufacture of extracts, as well as the storage, delivery and clinical inspection of drugs.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 16 May 1949
- Employees
- 6,457
- Website
- ds-pharma.co.jp ↗
Leadership
Pay as last reported
- Mr. Toru KimuraPresident, Chief Executive Officer, Representative Director, since 2015
- Mr. Motoyuki SakaiExecutive Vice President, Representative Director, since 2024
- Mr. Hiroyuki BabaManaging Executive Officer, since 2015
- Mr. Hideyuki HaradaManaging Executive Officer, Deputy Head of Japan Business Unit
- Ms. Atsuko HiguchiManaging Executive Officer
- Mr. Yoshiharu IkedaManaging Executive Officer, Head of Japan Business Unit, since 2010
- Mr. Shigeyuki NishinakaManaging Executive Officer, since 2017
- Mr. Tsutomu NakagawaExecutive Officer, President and CEO of Subsidiary, Director, since 2022
- Ms. Adele GulfoExecutive Officer
- Mr. Koichi KozukiExecutive Officer, Chief Director of Reliability Assurance, Deputy Head of Japan Business Unit
- Mr. Naoki NoguchiExecutive Officer, Director of Corporate Communication
- Ms. Yumi SatoExecutive Officer, Chief Director of Development
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 80
- Environment
- 99
- Social
- 99
- Governance
- 41
- Direct emissions (scope 1)
- 27,829 t
- Energy emissions (scope 2)
- 26,518 t
- Value chain emissions (scope 3)
- 364,870 t
- Women in the workforce
- 40.5%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Sumitomo Dainippon Pharma Co Ltd boasts several strengths that contribute to its success and market position. Firstly, the company has a robust product portfolio consisting of a wide range of pharmaceutical products, allowing it to cater to diverse customer needs. This diverse portfolio acts as a strong competitive advantage in the industry.
- Secondly, Sumitomo Dainippon Pharma has a strong focus on research and development (R&D). The company invests significantly in R&D activities to develop innovative drugs and therapies, positioning itself as an industry leader in terms of scientific advancements and cutting-edge solutions.
- Additionally, the company has a global presence with strategic partnerships and widespread distribution networks. This enables Sumitomo Dainippon Pharma to tap into various international markets and establish a strong foothold in different regions.
Weaknesses
- Sumitomo Dainippon Pharma also faces some weaknesses that can impact its operations and growth. One weakness is the company's heavy reliance on a few key products for a significant portion of its revenue. This concentration exposes the company to risks such as patent expiration or market competition, which could potentially impact its financial performance.
- Another weakness is the limited market share in certain geographies. While the company has a global presence, it may face challenges in penetrating and expanding its market reach in specific regions where it has less visibility or established competition.
Opportunities
- Sumitomo Dainippon Pharma can leverage several opportunities to drive its growth and market position further. One opportunity lies in the increasing demand for healthcare and pharmaceutical products globally. The company can capitalize on this by expanding its product portfolio and exploring new therapeutic areas or markets.
- Furthermore, advancements in technology and digital healthcare present opportunities for Sumitomo Dainippon Pharma. Embracing digital solutions, such as telemedicine platforms or personalized medicine, can enhance patient experiences, improve treatment outcomes, and potentially open new revenue streams for the company.
Threats
- Sumitomo Dainippon Pharma faces certain threats that may impact its business operations. One key threat is the stringent regulations and compliance requirements within the pharmaceutical industry. Non-compliance or changes in regulations can lead to delays in product launches, increased costs, or even legal issues, which can significantly impact the company's operations and reputation.
- Additionally, the presence of intense competition in the pharmaceutical market poses a threat to Sumitomo Dainippon Pharma. Rival companies, with established market positions, strong product pipelines, or larger marketing budgets, can potentially outperform or outmaneuver the company in terms of market share, customer acquisition, and brand recognition.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.